Wire · opportunities
Merck's TROP2 ADC extends survival in pivotal gastroesophageal cancer trial
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 20 November 2026 · Fusion42 review
Merck's sacituzumab tirumotecan (sac-TMT), a TROP2-directed antibody-drug conjugate, significantly extended overall survival in a global phase 3 trial for advanced gastroesophageal adenocarcinoma, marking a second major global success for Merck's TroFuse program.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
You can now position against established TROP2 competitors by targeting underexplored cancers like gastroesophageal adenocarcinoma where survival gains are proven. This readout opens patient markets that frontline ADCs have yet to impact.
◆ Coverage
1 source · 20 Nov 2026
◆ Related on Wire
◆ Topics